NCT02193724 is a clinical trial of Skin Biopsy in Retinoblastoma, sponsored by St. Jude Children's Research Hospital.

Who is sponsoring NCT02193724?

NCT02193724 is sponsored by St. Jude Children's Research Hospital.

What drugs are being tested in NCT02193724?

Interventions in NCT02193724: Skin Biopsy, Blood Draw.

What condition does NCT02193724 study?

NCT02193724 studies Retinoblastoma.

Is NCT02193724 still recruiting?

NCT02193724 is currently completed. Last updated 23 October 2020.

Last reviewed 2020-10-23 · How we verify

NCT02193724

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma

Completed Last updated 23 October 2020

What this trial tests

trial testing Skin Biopsy in Retinoblastoma in 15 participants. Completed in 23 August 2019.

Timeline

4 November 2014

Primary endpoint
23 August 2019

23 August 2019

Quick facts

Lead sponsor	St. Jude Children's Research Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	15
Start date	4 November 2014
Primary completion	23 August 2019
Estimated completion	23 August 2019
Sites	1 location across United States

Drugs / interventions tested

Skin Biopsy
Blood Draw — full drug profile →

Conditions studied

Retinoblastoma — all drugs for Retinoblastoma →

Sponsor

St. Jude Children's Research Hospital

Who can join

Eligibility, any sex, with Retinoblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to determine if human RB1-deficient induced pluripotent stem cells (iPSCs) can produce retina, and, furthermore, can give rise to retinoblastoma in culture. This unique opportunity to study the initiation of retinoblastoma in the developing retina will shed light on the cell of origin for retinoblastoma and allow the investigators to study the earliest molecular and cellular events in retinoblastoma tumorigenesis. OBJECTIVES: * To establish the feasibility of producing induced pluripotent stem cells (iPSCs) from retinoblastoma patients with germline RB1 mutations (RB1-deficient iPSCs). * To validate human RB1-deficient iPSCs by confirming karyotype, pluripotency and RB1 mutation. * To differentiate the RB1-deficient iPSCs into retina as a model of the initiation of retinoblastoma in the developing retina.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Ethical and Safety Issues of Stem Cell-Based Therapy.
Volarevic V, Markovic BS, Gazdic M, Volarevic A, et al · · 2018 · cited 552× · PMID 29333086 · DOI 10.7150/ijms.21666
Retinoblastoma from human stem cell-derived retinal organoids.
Norrie JL, Nityanandam A, Lai K, Chen X, et al · · 2021 · cited 81× · PMID 34315877 · DOI 10.1038/s41467-021-24781-7
Cell therapy in acute respiratory distress syndrome.
Horie S, Gonzalez HE, Laffey JG, Masterson CH. · · 2018 · cited 44× · PMID 30416812 · DOI 10.21037/jtd.2018.08.28
Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies.
Kalra RS, Dhanjal JK, Das M, Singh B, et al · · 2021 · cited 16× · PMID 34685537 · DOI 10.3390/cells10102558
Human Stem Cell Transplantation for Retinal Degenerative Diseases: Where Are We Now?
Alcalde I, Sánchez-Fernández C, Martín C, De Pablo N, et al · · 2022 · cited 7× · PMID 35056410 · DOI 10.3390/medicina58010102

Verify or expand the search:

Other trials of Skin Biopsy

Trials testing the same drug.

NCT07349771 — Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoie · Phase 2 · not yet recruiting
NCT07011810 — Axatilimab for Sclerotic Chronic Graft-versus-Host Disease · Phase 2 · recruiting
NCT05515692 — Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease · EARLY_PHASE1 · withdrawn
NCT05739149 — A Study to Evaluate Microvessel Ultrasound Imaging of Wound Healing in Patients With Chronic Ulcers · NA · recruiting
NCT05993871 — Diabetic Small Fiber Neuropathy: Clinical, Electrophysiological and Neurosonographic Study · completed

Other recruiting trials for Retinoblastoma

Currently open trials in the same condition.

NCT06725173 — Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra- · recruiting
NCT06972602 — High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed · EARLY_PHASE1 · recruiting
NCT06424301 — Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma · EARLY_PHASE1 · recruiting
NCT06367530 — Trilateral Retinoblastoma: Incidence and Outcomes · recruiting
NCT05650749 — GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma · Phase 1 · recruiting

Other St. Jude Children's Research Hospital trials

Trials by the same sponsor.

NCT07222735 — Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcoma · Phase 1 · recruiting
NCT07085338 — A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Pat · Phase 2 · recruiting
NCT05664113 — Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction i · Phase 1 · recruiting
NCT06993688 — Revealing Information Genuinely & Honestly Across Time - Communication Preferences Visit · NA · recruiting
NCT06326463 — CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02193724 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Jude Children's Research Hospital
Last refreshed: 23 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02193724.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing